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Abstract
Background: Ingestion of the calorically dense compound alcohol may cause metabolic 
disturbances including hypoglycaemia, hepatic steatosis and insulin resistance, but 
the underlying mechanisms are uncertain. The gastrointestinal tract is well recognised 
as a major influencer on glucose, protein and lipid metabolism, but its role in alcohol 
metabolism remains unclear.
Objective: To examine the effects of oral and intravenous alcohol, respectively, on plasma 
concentrations of several gluco-regulatory hormones including serum/plasma insulin, 
C-peptide, glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucagon-like 
peptide 1 (GLP-1) and fibroblast growth factor 21 (FGF21).
Design and methods: In a double-blinded, randomised, crossover design, we subjected 12 
healthy men to intragastric ethanol infusion (IGEI) and an isoethanolaemic intravenous 
ethanol infusion (IVEI) (0.7 g alcohol per kg body weight), respectively, on two separate 
experimental days.
Results: Isoethanolaemia during the two alcohol administration forms was obtained 
(P = 0.38). During both interventions, plasma glucose peaked after ~30 min and 
thereafter fell below baseline concentrations. GIP and GLP-1 concentrations were 
unaffected by the two interventions. Insulin concentrations were unaffected by IGEI but 
decreased during IVEI. C-peptide, insulin secretion rate and glucagon concentrations 
were lowered similarly during IGEI and IVEI. FGF21 concentrations increased dramatically 
(nine-fold) and similarly during IGEI and IVEI.
Conclusions: Alcohol does not seem to affect the secretion of incretin hormones but 
decreased insulin and glucagon secretion independently of gut-derived factors. IGEI as well 
as IVEI potently stimulate FGF21 secretion indicating a gut-independent effect of alcohol on 
FGF21 secretion in humans.
Introduction
The majority of the world’s population consumes 
alcohol occasionally and alcohol-related diseases 
represent a major healthcare burden worldwide (1). 
Consumption of alcohol is related to several metabolic 
processes affecting glucose metabolism (2). It is well 
known that acute alcohol ingestion increases the risk of 
hypoglycaemia; most likely due to inhibitory effects of 
alcohol on hepatic gluconeogenesis (3). In addition, it is 
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well known that chronic alcohol consumption may 
cause hepatic steatosis which in some individuals leads 
to insulin resistance and impaired glucose tolerance (4, 
5). However, the exact mechanisms underlying these 
pathophysiological processes have not been identified. 
Alcohol has been found both to increase and decrease 
serum insulin concentrations under various conditions 
and administration forms (6, 7, 8), and results from studies 
investigating the effect of alcohol on plasma glucagon 
concentrations are ambiguous as well (9, 10). Likewise, 
the effect of alcohol on the secretion of the gut-derived 
insulinotropic incretin hormones, glucose-dependent 
insulinotropic polypeptide (GIP) and glucagon-like 
peptide 1 (GLP-1) remains unclear (6, 11, 12). Recently, 
alcohol was shown to constitute a potent stimulator of 
the liver-derived hormone fibroblast growth factor 21 
(FGF21) in humans (13, 14). In rodents, FGF21 has been 
shown to increase insulin sensitivity (15) and decrease 
hepatic glucose production, and thus, play an important 
role in the regulation of plasma glucose concentrations. 
In humans, FGF21 is mainly secreted from the liver in 
response to fructose (16), high-carbohydrate diet (17) 
and oral alcohol ingestion (13, 14). It is not known how 
alcohol mediates FGF21 secretion and it remains obscure 
whether pancreatic or gut-derived hormones are involved 
in alcohol-induced secretion of FGF21.
The gastrointestinal tract plays a major role in 
glucose, protein and lipid metabolism; and energy-
rich macronutrients, that is, carbohydrate, protein and 
lipid, stimulate insulin secretion to a larger extent when 
administered orally compared to intravenously (18, 19, 20, 
21). This phenomenon is called the incretin effect and is 
due to nutrient-induced secretion of GIP and GLP-1 from 
enteroendocrine K and L cells, respectively. It remains 
unknown whether the calorically dense compound 
alcohol, which can be considered a macronutrient, 
induces an incretin effect, and the effects of intragastric 
ethanol infusion (IGEI) and isoethanolaemic intravenous 
ethanol infusion (IVEI), respectively, have never been 
evaluated.
In this study we investigated (1) if alcohol elicits an 
incretin effect, (2) the potential role of the gut in alcohol 
metabolism and (3) alcohol’s effect on glucose metabolism.
Materials and methods
Approval and ethics
The study was approved by the Scientific-Ethical Committee 
of the Capital Region of Denmark (identification no. 
H-16026085) and the Danish Data Protection Agency and 
registered on Clinicaltrials.gov (clinical trial Identifier: 
NCT03348371). The study was conducted according to 
the Helsinki Declaration II and written informed consent 
was obtained from all participants.
Subjects
We included 12 healthy Caucasian men between 20 and 
50 years of age (characteristics in Table 1). Key inclusion 
criteria were body mass index (BMI) between 19 and 
25 kg/m2, weekly alcohol intake of less than 14 units of 
alcohol (1 unit = 12 g alcohol), fasting plasma glucose 
<6 mmol/L, haemoglobin A1c <6% (<42 mmol/mol), 
normal haemoglobin and written informed consent. 
Key exclusion criteria were liver disease or other alcohol-
related disease and nephropathy and first-degree 
relatives with type 1 diabetes, type 2 diabetes and/or 
liver disease.
Experimental procedures
The study comprised two separate experimental days 
performed in randomised order (using a randomisation list 
generated from www.random.org). On the experimental 
days, the participants received an infusion of alcohol either 
via an intravenous catheter or intragastrically through a 
nasogastric tube (to ensure blinding and avoid the initial 
metabolism of alcohol in the mucosa of the mouth (22)). 
The alcohol infusions were designed (see below) to obtain 
isoethanolaemia on the two study days. The route of 
alcohol administration was double-blinded using similarly 
looking saline infusions administered simultaneously via 
the opposite route of administration, that is, intravenous 
placebo was given on the day of intragastric alcohol 
Table 1 Characteristics of participants.
Participants (n = 12) Mean ± s.d.
Sex (male/female) 12/0
Age (years) 25 ± 3.9
Body weight (kg) 77 ± 7.9
Height (m) 1.85 ± 0.1
Body mass index (kg/m2) 23 ± 2.6 
Fasting plasma glucose (mmol/L) 5.2 ± 0.4
Haemoglobin A1c (%) 5.3 ± 0.4
Haemoglobin A1c (mmol/mol) 30 ± 2.8
HOMA2-IR 0.7 ± 0.2
ALAT (U/L) 28 ± 11
Creatinine (μmol/L) 87 ± 12
ALAT, alanine aminotransferase; HOMAR2-IR, homeostasis model 
assessment 2 of insulin resistance (44); s.d., standard deviation.
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administration and vice versa. A laboratory technician 
was responsible for preparing the infusions; this person 
was otherwise not involved in the study. The participants 
abstained from alcohol intake for 5 days prior to each of the 
experimental days and met after an overnight fast (10 h). 
An intravenous catheter was inserted into an antecubital 
vein in each arm; one for infusion (alcohol or placebo) 
and one for blood sample collection, and a nasogastric 
tube was inserted. The hand of the forearm, from which 
blood samples were drawn, was wrapped in a heating pad 
(~42ºC) throughout the experiment for arterialisation of 
the blood. At time point 0 min, the participants received 
alcohol (0.70 g alcohol per kg body weight (20% alcohol 
solution (v/w)) mixed in isotonic saline water, equivalent 
to 20.3 kJ per kg body weight) or placebo (saline) via the 
gastric tube for 5 min or alcohol (same amount) was infused 
for 45 min through the intravenous catheter. The time for 
the intravenous infusion was based on a study made by 
Christiansen et al. (8) in which a bolus of 0.66 g alcohol/kg 
was given orally and peaked after 45–60 min. Blood samples 
were sampled at time points −30, −15, 0, 15, 30, 45, 60, 90, 
120, 180 and 240 min. For bedside measurement of plasma 
glucose, blood was collected in sodium-fluoride tubes and 
centrifuged (7400 g) immediately for 30 s. For the analyses 
of insulin and C-peptide in serum, blood was sampled in 
plain tubes and left to coagulate for 20 min. For analyses 
of FGF21, GIP, GLP-1 and glucagon in plasma, blood was 
collected in chilled EDTA tubes containing EDTA and a 
specific dipeptidyl peptidase 4 (DPP-4) inhibitor (valine 
pyrrolidide, 0.01 mmol/L, Novo Nordisk). For the analysis 
of alcohol, blood was collected in lithium-heparin tubes. 
All tubes were centrifuged for 15 min at 2000 g and 4°C. 
Plasma and serum samples were stored at −20 and −80°C, 
respectively, until analyses.
Analyses
Glucose was analysed on a glucose analyzer (YSI 2300 STAT 
glucose analyzer, Xylem Inc., Yellow Springs, OH, USA). 
Plasma alcohol was analysed by reflectance photometry 
at 340 nm (Vitros, Ortho-Clinical Diagnostics). Serum 
insulin and C-peptide were analysed with two-sided 
electrochemiluminescence assays (Roche/Hitachi Modular 
Analytics; Roche Diagnostics). Total plasma GLP-1 (23), 
total plasma GIP (21) and glucagon (24) were measured 
by RIAs as previously described. Intact (i.e. full-length and 
active) plasma FGF21 was analysed by ELISA using detection 
and capture antibodies targeted to the N and C-termini of 
the full-length human protein (EagleBiosciences, Nashua 
NH, USA Cat#: F21K31-K01) (13).
Calculations and statistical analysis
Baseline values for each endpoint were calculated as 
a mean of time points −30, −15 and 0 min for the 
plasma/serum samples. Area under the curve (AUC) 
was calculated by the trapezoid rule and compared 
with paired t tests. Changes over time were calculated 
using two-way repeated-measures ANOVA and Tukey´s 
multiple comparison was used to test for differences over 
time, between alcohol administration forms and for the 
interaction between intervention and time. Differences 
resulting in P values <0.05 were accepted as statistically 
significant. Statistical analyses and graphs were made 
using GraphPad Prism 7.02 (GraphPad Software, Inc.). 
Data are presented as mean ± s.d. unless otherwise stated.
Insulin secretion rates (ISRs) were calculated 
using EasyISEC 1.01 software based on C-peptide 
concentrations, age, height, weight and population-based 
variables for C-peptide kinetics as previously described 
(25). Insulin/glucose ratio was calculated for each data 
point. Insulinogenic index was calculated as the insulin 
delta value from baseline to 30 min divided by the glucose 
delta value from baseline to 30 min (Δinsulin0–30 min/
Δglucose0–30 min) (26). The presented gluco-metabolic 
results represent a sub-study of an investigation of hepatic 
inflammation (unpublished). Therefore, the sample size 
was calculated to detect a minimal difference of 15% in 
the inflammation marker CD163.
Results
Characteristics of participants are shown in Table 1. 
During the experiments, none of the participants 
reported unpleasant symptoms of intoxication like 
nausea, headache or vomiting. Three of the participants 
developed self-limiting superficial phlebitis after the 
alcohol infusion. One of the participants experienced 
symptomatic hypoglycaemia (plasma glucose 2.9 mmol/L) 
180 min after receiving IVEI after which the participant 
received a cup of juice to prevent further drop in plasma 
glucose. Therefore, only 11 participants are included in 
the two-way repeated-measurement ANOVA.
Alcohol
All participants started with a plasma ethanol concentration 
of 0 g/L on both days. Plasma concentrations increased 
immediately, rapidly and similarly after the two alcohol 
administration forms (Fig. 1A, Table 2). There were no 
significant differences in plasma alcohol concentrations 
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between the two administration forms; therefore, 
isoethanolaemia was obtained (P = 0.38) (Fig. 1A and B, 
Table 2).
Glucose
Baseline plasma glucose concentrations were similar before 
IGEI and IVEI, respectively (P = 0.54) (Table 2). Plasma 
glucose concentrations showed significant changes over 
time (P < 0.0001) but not between interventions (P = 0.66) 
or for time × intervention (P = 0.21). During both alcohol 
administration forms, plasma glucose concentrations 
increased by ~0.4 mmol/L and hereafter slowly decreased 
to attain significantly lower concentrations compared 
to baseline after 240 min (4.5 ± 0.4 mmol/L (P = 0.009) 
and 4.6 ± 0.2 mmol/L (P = 0.002) after IGEI and IVEI, 
respectively) (Fig. 1C). AUCs for plasma glucose were 
similar during IGEI and IVEI (P = 0.20) (Fig. 1D, Table 2).
Insulin and C-peptide
We observed no significant differences between serum 
insulin concentrations at baseline or between AUCs 
during the two administration forms (Fig. 2A and B, 
Table 2). Serum insulin concentrations were unaffected 
by IGEI, whereas the concentrations declined to a mean 
nadir of 27 ± 12 pmol/L (P < 0.0001 and P = 0.04 compared 
to baseline and nadir of IGEI, respectively) at 55 ± 40 min 
during IVEI after which concentrations increased towards 
baseline (Fig. 2A). A significant difference was seen over 
time (P < 0.0001) and for time × intervention (P = 0.0064), 
but not for intervention (P = 0.18) evaluated using two-way 
repeated-measures ANOVA. Significant differences between 
serum insulin concentrations during IGEI and IVEI were 
observed for time points 15, 30 and 45 min (P = 0.013, 
P = 0.004 and P = 0.001, respectively) (Fig. 2A). Insulin/
glucose ratio fell significantly after alcohol administration 
compared to baseline (P < 0.0001 after both IGEI and IVEI); 
however, nadir after IVEI was significantly lower compared 
to IGEI (P = 0.04) (Fig. 3C and D, Table 2). Serum C-peptide 
concentrations were similar at baseline and decreased 
similarly after both alcohol administration forms to reach 
concentrations below normal range for healthy individuals 
(27) and significantly below baseline concentrations 
(P < 0.0001 for both IGEI and IVEI) (Fig. 2C and D, Table 
2). There was no difference between baseline values and 
AUCs for ISR during the two administration forms (Fig. 
3A and B, Table 2). ISR fell similarly and significantly after 
both alcohol administration forms compared to baseline 
(P < 0.0001 after both IGEI and IVEI). Beta cell function 
evaluated by insulinogenic index was more reduced after 
IVEI compared to IGEI (P = 0.05) (Table 2).
Glucagon
Baseline plasma glucagon concentrations were similar on 
the two experimental days and decreased significantly 
(P = 0.0004 and P < 0.0001 for IGEI and IVEI, respectively) 
and similarly compared to baseline after both forms of 
alcohol administration, reaching mean nadirs at time 
Figure 1
Plasma ethanol concentrations (A) and 
corresponding area under the curve (AUC) values 
(B) and plasma glucose concentrations (C) and 
corresponding AUCs (D) during intragastric 
alcohol infusion (IGEI) (black circles) and 
intravenous alcohol infusion (IVEI) (white circles). 
Data are mean ± s.e.m.
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Table 2 Alcohol, glucose, insulin, C-peptide, glucagon, GIP, GLP-1 and FGF21.
Administration form: IGEI IVEI T test (P values)
Alcohol
 Baseline (g/L) 0 ± 0 0 ± 0
 AUC0–240 min (g/L × min) 251 ± 26 256 ± 30 0.38
 Peak plasma concentration (g/L) 1.7 ± 0.3 1.8 ± 0.3 0.22
 Time to peak (min) 38 ± 18 44 ± 4.3 0.24
Glucose
 Baseline (mmol/L) 4.9 ± 0.3 4.9 ± 0.2 0.54
 AUC0-240 min (mmol/L × min) 1177 ± 65 1127 ± 186 0.30
 Peak plasma concentration (mmol/L) 5.3 ± 0.4 5.3 ± 0.3 0.34
 Time to peak (min) 36 ± 53 54 ± 60 0.65
Insulin
 Baseline (pmol/L) 53 ± 19 50 ± 18 0.67
 AUC0-240 min (pmol/L × min) 12 ± 4.0 11 ± 3.7 0.18
 Nadir (pmol/L) 36 ± 14 27 ± 12 0.04
 Time to nadir (min) 86 ± 98 55 ± 40 0.23
C-peptide
 Baseline (pmol/L) 321 ± 72 325 ± 87 0.82
 AUC0-240 min (pmol/L × min) 69 ± 17 69 ± 21 0.95
 Nadir (pmol/L) 242 ± 58 235 ± 74 0.77
 Time to nadir (min) 151 ± 106 105 ± 91 0.08
Insulin secretion rate
 Baseline (pmol/kg/min) 1.1 ± 0.3 1.1 ± 0.3 0.98
 AUC0-240 (pmol/kg/min × min) 220 ± 56 219 ± 53 0.97
 Nadir (pmol/kg/min) 0.6 ± 0.2 0.7 ± 0.2 0.94
 Time to nadir (min) 93 ± 104 86 ± 89 0.88
Insulin/glucose ratio
 Baseline (pmol/mmol) 11 ± 2.7 10 ± 2.5 0.60
 AUC0-240 (pmol/mmol × min) 2504 ± 786 2153 ± 687 0.20
 Nadir (pmol/mmol) 7.0 ± 2.5 5.3 ± 1.8 0.04
 Time to nadir (min) 61 ± 88 44 ± 4.1 0.52
Beta cells
 Insulinogenic index −29 ± 88 −127 ± 152 0.05
Glucagon
 Baseline (pmol/L) 6.0 ± 3.8 5.1 ± 1.7 0.45
 AUC0-240 min (pmol/L × min) 1013 ± 678 1227 ± 552 0.20
 Nadir (pmol/L) 2.2 ± 1.5 2.5 ± 1.6 0.37
 Time to nadir (min) 41 ± 34 40 ± 27 0.91
GIP
 Baseline (pmol/L) 17 ± 7.7 15 ± 4.6 0.14
 AUC0-240 min (pmol/L × min) 2479 ± 1071 2496 ± 1240 0.96
 Peak plasma concentration (pmol/L) 18 ± 5.6 18 ± 7.8 0.89
 Time to peak (min) 70 ± 81 160 ± 73 0.01
GLP-1
 Baseline (pmol/L) 19 ± 7.9 21 ± 9.4 0.52
 AUC0-240 min (pmol/L × min) 5093 ± 2103 4266 ± 1707 0.24
 Peak plasma concentration (pmol/L) 30 ± 9.2 30 ± 7.9 0.67
 Time to peak (min) 44 ± 34 65 ± 113 0.56
FGF21
 Baseline (pg/mL) 31 ± 35 30 ± 35 0.89
 AUC0-240 min (pg/mL × min) 37,738 ± 27,855 32,592 ± 20,728 0.21
Differences between groups were compared with paired T test. Data are mean ± s.d.
AUC, area under the curve; FGF21; fibroblast growth factor 21; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; IGEI, 
intragastric alcohol infusion; IVEI, intravenous alcohol infusion.
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point 40 ± 27 min (IVEI) and time point 41 ± 34 min (IGEI), 
respectively, after which glucagon concentrations returned 
towards baseline concentrations (Fig. 4A and B, Table 2).
GIP and GLP-1
Baseline plasma concentrations of GIP and GLP-1, 
respectively, were similar on both experimental days 
and no significant differences in GIP or GLP-1 responses 
(as assessed by AUCs) were observed between IGEI and 
IVEI (Fig. 5A and B, Table 2). Similar peak plasma GLP-1 
(P = 0.67) and GIP (P = 0.89) concentrations, respectively, 
were observed during IGEI and IVEI. We observed a small 
but significant variation over time in both plasma GIP 
(P < 0.0001) and plasma GLP-1 (P = 0.01) concentrations 
during the two experimental days. For plasma GIP a 
significant difference was seen for time × intervention 
(P = 0.0001), but not for intervention (P = 0.10) evaluated 
using two-way repeated-measures ANOVA. A difference 
was observed between IGEI and IVEI at the time points 
Figure 2
Serum insulin concentrations (A) and 
corresponding area under the curve (AUC) values 
(B) and serum C-peptide concentrations (C) and 
corresponding AUCs (D) during intragastric 
alcohol infusion (IGEI) (black circles) and 
intravenous alcohol infusion (IVEI) (white circles). 
Asterisks indicate statistically significant 
interactions between intervention and time 
evaluated by multiple comparisons. *P < 0.05; 
**P < 0.005. Data are mean ± s.e.m.
Figure 3
Insulin secretion rate (ISR) (A) and corresponding 
area under the curve (AUC) values (B) and insulin/
glucose ratio (C) and corresponding AUCs (D) 
during intragastric alcohol infusion (IGEI) (black 
circles) and intravenous alcohol infusion (IVEI) 
(white circles). Data are mean ± s.e.m.
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15, 30 and 60 min (P = 0.005, P = 0.005 and P = 0.0004, 
respectively) (Fig. 5A and B).
FGF21
There was no significant difference between baseline 
plasma FGF21 concentrations during the two experimental 
days (Table 2). Plasma FGF21 concentrations started to 
increase 60 min after ethanol administration (~20 min 
after serum ethanol had peaked) and after 240 min 
FGF21 had increased approximately nine-fold from 
31 ± 35 to 270 ± 215 pg/mL for IGEI and from 30 ± 35 to 
268 ± 217 pg/mL for IVEI (without signs of peaking and 
with no difference between the two administration forms 
(P = 0.97)) (Fig. 6A and B, Table 2).
Discussion
In this study we provide a detailed description of how 
acute alcohol (administered intragastrically as well as 
intravenously) affects circulating concentrations of 
insulin, glucagon, GIP, GLP-1 and the liver-derived 
hormone FGF21. Overall, alcohol seems to (1) inhibit the 
secretion of both insulin and glucagon (independently of 
administration form), (2) have little or no effect on the 
secretion of the incretin hormones GIP and GLP-1 and (3) 
dramatically increase the secretion of FGF21 during both 
IGEI and IVEI.
Alcohol lowers glucose concentrations regardless 
of administration form
Alcohol consumption is associated with increased risk 
of hypoglycaemia (3). However, the mechanism(s) 
behind this is unclear. We observed an initial increase in 
plasma glucose concentration ~30–35 min after alcohol 
administration and a decline to below baseline values 
after ~3.5 h. The decline could be due to the continued 
fasting of the participants and not the incretin hormones, 
insulin or the alcohol infusion itself. We did not include a 
placebo intervention (intragastric and intravenous placebo 
Figure 4
Plasma glucagon concentrations (A) and 
corresponding area under the curve (AUC) values 
(B) during intragastric alcohol infusion (IGEI) 
(black circles) and intravenous alcohol infusion 
(IVEI) (white circles). Data are mean ± s.e.m.
Figure 5
Plasma glucose-dependent insulinotropic 
polypeptide (GIP) concentrations (A) and 
corresponding area under the curve (AUC) values 
(B), and plasma glucagon-like peptide 1 (GLP-1) 
concentrations (C) and corresponding AUCs (D) 
during intragastric alcohol infusion (IGEI) (black 
circles) and intravenous alcohol infusion (IVEI) 
(white circles). Asterisks indicate statistically 
significant interactions between intervention and 
time were evaluated by multiple comparisons. 
**P < 0.005; ***P < 0.0005. Data are mean ± s.e.m.
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administration) which is a limitation of our study. However, 
previous studies of saline infusions (intraduodenally and 
intravenous) in healthy subjects observed no changes in 
the secretion of pancreatic or incretin hormones (28, 29). 
In addition to the reduced glucagon concentrations we 
observed after ethanol administration (discussed below), 
hepatic metabolism of ethanol may contribute to the risk 
of hypoglycaemia. Alcohol is metabolised in the liver by 
alcohol dehydrogenase to acetaldehyde and subsequently 
to acetate. These reactions reduce nicotinamide adenine 
dinucleotide (NAD+) to NADH and thus facilitate a 
decline in the NAD+/NADH ratio, which inhibits several 
dehydrogenases essential for gluconeogenesis (2, 3).
Alcohol reduces insulin secretion after  
IGEI as well as IVEI
High alcohol consumption may cause insulin resistance 
(30, 31). Traditionally, the mechanism is believed to 
involve alcohol-induced increase in NADH inhibiting 
fatty acid oxidation, promoting steatosis and inducing 
liver inflammation (32, 33). The direct effect of alcohol on 
insulin secretion has been investigated with ambiguous 
results (6, 7, 10). Insulin concentrations decreased after 
intravenous alcohol administration in healthy individuals 
(7). In contrast, pre-treatment with oral alcohol increased 
AUCs of insulin and C-peptide during an intravenous 
glucose tolerance test in healthy individuals (6). Also, 
glucose and insulin concentrations increased after oral 
alcohol administration and subsequent continuous 
intravenous alcohol infusion maintaining constant alcohol 
concentration of about 2 mmol/L in healthy subjects (10). 
In the present study, we observed no stimulating effect of 
alcohol on insulin concentrations after IGEI but a small 
decrease during IVEI. In line with this, insulin/glucose ratios 
decreased after alcohol administration reaching a lower nadir 
after IVEI. This could be due to the relatively higher portal 
alcohol concentrations after IGEI reducing hepatic insulin 
extraction more than isoethanolaemic IVEI. In contrast, 
C-peptide undergoes negligible hepatic extraction which is 
why circulating C-peptide constitutes a more precise measure 
of pancreatic insulin secretion than circulating insulin (34). 
Interestingly, we observed a decline in C-peptide and ISR 
after both administration forms, which suggests that alcohol 
suppresses insulin secretion independently of alcohol’s 
potential effects in the gut. Also, beta cell function evaluated 
by insulinogenic index appeared to be impaired after IVEI 
compared to IGEI. Nevertheless, the insulinogenic index 
was negative after both administration forms, which may 
indicate an impaired beta cell function after acute alcohol 
intake. The insulinogenic index is a validated measure of 
beta cell function after an oral glucose tolerance test and its 
use during the conditions investigated in the present study 
may be questioned. Moreover, we used only a single dose of 
alcohol; repeated dosing may show different results.
Alcohol decreases glucagon concentrations 
regardless of intestinal stimulation
The effect of alcohol on glucagon secretion has been studied 
with inconsistent results (9, 10). Intravenous administration 
of alcohol enhanced alanine-stimulated glucagon release 
(9), whereas the counter-regulatory glucagon response to 
insulin-induced hypoglycaemia in young healthy men 
was delayed and diminished after oral and subsequent 
maintenance by intravenous alcohol administration (10). 
In the latter study, alcohol administration had no effect on 
fasting glucagon concentrations (10) which contrasts to 
our findings. A direct inhibitory effect of alcohol on the 
alpha cells or the initially increased glucose concentrations 
may explain the decline in glucagon concentrations 
during both administration forms in the present study. 
Nonetheless, the present results demonstrate that the effect 
of alcohol on glucagon secretion is not due to mechanisms 
derived from an intestinal stimulus.
Alcohol does not elicit an incretin effect
The incretin effect is defined as the relative increment in 
insulin response to oral vs intravenous administration 
Figure 6
Plasma fibroblast growth factor 21 (FGF21) 
concentrations (A) and corresponding area under 
the curve (AUC) values (B) during intragastric 
alcohol infusion (IGEI) (black circles) and 
intravenous alcohol infusion (IVEI) (white circles). 
Data are mean ± s.e.m.
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of glucose during similar plasma glucose concentrations 
(due to insulinotropic actions of the gut-derived incretin 
hormones) (35). The incretin effect of alcohol has 
never been investigated properly (comparing incretin 
concentrations after IGEI vs IVEI). However, the effect of 
alcohol on circulating concentrations of incretin hormones 
has previously been studied under various conditions and 
with inconsistent results (6, 11, 12). Oral alcohol did not 
have a significant effect on GLP-1 secretion before an 
intravenous glucose tolerance test in healthy participants 
(6). In addition, orally administered alcohol did not 
affect GLP-1 secretion in fasting healthy individuals (11). 
However, oral alcohol administered during a fat-rich 
mixed meal suppressed the early postprandial GIP and 
GLP-1 responses in patients with type 2 diabetes (12). In 
the present study, we did not observe any physiologically 
relevant changes in GLP-1 or GIP concentrations during 
IGEI or IVEI. This suggests that alcohol – unlike other 
macronutrients – does not stimulate GIP or GLP-1 after 
intragastric administration, and, combined with the lack of 
any stimulatory effect of alcohol on insulin secretion (see 
above), that alcohol intake does not elicit an incretin effect.
Alcohol increases circulating FGF21 concentrations 
dramatically regardless of administration route
Studies in rodents have shown that exogenous FGF21 
decreases the taste preference for sweets and alcohol (14, 
36). Also, recent human evidence supports the notion 
that the FGF21 gene plays a role in taste preference 
for sweets and alcohol consumption (37, 38, 39, 40) 
positioning FGF21 as a potential negative regulator of 
alcohol consumption. Furthermore, FGF21 has been 
shown to increase insulin sensitivity and decrease hepatic 
glucose production in mice (15) and an FGF21 analogue 
has been shown to exert insulinotropic actions in 
patients with type 2 diabetes (41). In the present study, 
FGF21 concentrations increased dramatically, which is 
consistent with previous studies (13, 14). This could point 
towards FGF21 as a factor linking alcohol intake and 
glucose metabolism and supports the existence of a liver-
brain feedback loop; ingestion of alcohol increases FGF21 
secretion which in turn may decrease alcohol intake via 
the central nervous system (39, 40). Therefore, FGF21 
may not only constitute a potential future antidiabetic 
agent but perhaps also a potential target for patients 
diagnosed with alcohol use disorder. Interestingly, the 
temporal secretion of FGF21 was not parallel to the 
plasma alcohol concentrations. As previously described 
(14), we observed plasma alcohol to peak ~40 min after 
alcohol administration, whereas plasma FGF21 rose after 
~60 min and kept rising throughout the study period 
(240 min). Samms et  al. (42) found FGF21 secretion to 
be stimulated by increased insulin concentrations, and 
others have found acute glucagon administration to cause 
an increase in FGF21 concentrations in humans (43). 
However, in the present study we saw no increases in 
insulin or glucagon; precluding that elevations in insulin 
and/or glucagon are required for FGF21 secretion. Rather, 
FGF21 may be secreted as a direct response to alcohol 
exposure and FGF21 actions could result in the reduced 
insulin secretion after alcohol administration seen in this 
study. However, the mechanisms underlying alcohol-
induced FGF21 secretion and actions related to insulin 
secretion remain to be established.
Conclusion
Alcohol – unlike other macronutrients (i.e. carbohydrate, 
lipid and protein) – does not seem to stimulate GIP or 
GLP-1 after intragastric administration. Moreover, alcohol 
appears to decrease the secretion of both glucagon and 
insulin from the pancreas independently of the route of 
administration (intragastrically vs intravenously). The 
higher concentrations of circulating FGF21 observed after 
both alcohol administration forms, suggest alcohol to be 
a stimulator of FGF21 secretion acting independently of 
the gut (and gut-derived factors), glucagon and insulin.
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